Search

Your search keyword '"Sánchez-Carazo, Jose"' showing total 29 results
Start Over Author "Sánchez-Carazo, Jose" Language english
29 results on '"Sánchez-Carazo, Jose"'

2. Lower limb lymphangioma circumscriptum: The guiding sign for the diagnosis of Maffucci syndrome.

Author

Martínez‐Doménech, Álvaro, Esteve‐Martínez, Altea, Pérez‐Pastor, Gemma, Sánchez‐Carazo, Jose Luis, and Pérez‐Ferriols, Amparo

Subjects
SYNOVIOMA, LYMPHANGIOMAS, DIAGNOSIS, SYNDROMES, SOMATIC mutation
Abstract

Maffucci syndrome is a rare condition that affects the skin and bones, particularly the limbs. It is characterized by multiple enchondromas (benign bone tumors) and lymphovascular proliferations, such as hemangiomas and venous malformations. Lymphatic malformations, specifically lymphangiomas, have been reported in a few cases. The syndrome is associated with genetic mutations and carries a risk of developing various malignancies. The article presents a case of Maffucci lymphangioma syndrome in a woman with lesions on her lower limb. A skin biopsy confirmed the diagnosis, and genetic testing revealed a mutation associated with Maffucci syndrome. The authors emphasize the importance of recognizing this condition and conducting appropriate follow-up due to the risk of malignant transformation and other malignancies. [Extracted from the article]

Published
2024
Full Text
View/download PDF

3. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

Author

Pérez Zafrilla, Beatriz, Muñoz-Santos, Carlos, Mendiola-Fernández, Victoria, Sánchez Roldán, Cristina, Ruiz-Genao, Diana, Echeverría, Begoña, Galiano Mejías, Sagrario, Dávila-Seijo, Paula, Dauden, Esteban, Descalzo, M.A., Carretero, Gregorio, Carrascosa, José-Manuel, Vanaclocha, Francisco, Gómez-García, Francisco-José, De la Cueva-Dobao, Pablo, Herrera-Ceballos, Enrique, Belinchón, Isabel, López-Estebaranz, José-Luis, Alsina, Merce, Sánchez-Carazo, José-Luis, Ferrán, Marta, Torrado, Rosa, Ferrandiz, Carlos, Rivera, Raquel, Llamas, Mar, Jiménez-Puya, Rafael, and García-Doval, Ignacio

Published
2017
Full Text
View/download PDF

5. Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients).

Author

Melgosa Ramos, Francisco Javier, Mateu Puchades, Almudena, Guillén Climent, Santiago, Galarreta Pascual, Marta, Saéz Belló, Marina, Martínez Ferrer, María Angels, Alberola, Fernando Toledo, Magdaleno Tapial, Jorge, Sánchez Carazo, Jose Luís, Díaz, Javier Matáix, Schneller‐Pavelescu Apetrei, Luca, García Fernández, Laura, González Villanueva, Iris, Belinchón Romero, Isabel, Martín Jiménez, Sergio, and Santos Alarcón, Sergio

Published
2023
Full Text
View/download PDF

7. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

Author

Daudén, Esteban, Llamas-Velasco, Mar, Santamaría, Cristina, Carretero, Gregorio, Vilar-Alejo, Jaime, Madrid Álvarez, Blanca, Rivera, Raquel, García-Donoso, Carmen, Gomis, Ma del Mar Onteniente, Batista Cabrera, Diana, Ferrándiz, Carlos, Manuel Carrascosa, José, Ballescá, Ferrán, de la Cueva, Pablo, Molina Mejías, Patricia, Belinchón, Isabel, García Giner, Carlos, Perez, Alfred, Gómez-García, Fran J., Herrera-Ceballos, Enrique, Herrera-Acosta, Enrique, Martínez-García, Eliseo, Sánchez, Cristina, López-Estebaranz, José Luis, Patricia Ruiz-Genao, Diana, García Zamora, Elena, Ferrán Farrés, Marta, Alsina, Mercè, Riera, Josep, Pedregosa Fauste, Sara, Baniandrés, Ofelia, María Nieto Benito, Lula, Molina, Desiree, Sánchez-Carazo, José Luis, Sahuquillo-Torralba, Antonio, Botella-Estrada, Rafael, Pujol Marco, Conrad, Chaparro Aguilera, Natalia, Massó López, Verónica, Rodríguez Fernández-Freire, Lourdes, Mateu Puchades, Almudena, Santos, Sergio, Sáez Belló, Marina, Flórez Menéndez, Ángeles, Salgado, Laura, González Sixto, Beatriz, Abalde, Ma Teresa, Vilanova, Lucia, Perez Mariño, Alexandra, Eiris, Noemí, Prieto Marcos, Vicenta, García-Doval, Ignacio, Ángel Descalzo Gallego, Miguel, de Vega Martínez, Marina, Baniandrés-Rodríguez, Ofelia, Carrascosa, José Manuel, Nieto-Benito, Lula María, Fernández-Freire, Lourdes Rodríguez, Ruiz-Genao, Diana Patricia, Riera-Monroig, Josep, and Descalzo Gallego, Miguel Ángel

Published
2021
Full Text
View/download PDF

12. Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy: Patients Ineligible vs Eligible for Randomized Controlled Trials

Author

Garcia-Doval, Ignacio, Carretero, Gregorio, Vanaclocha, Francisco, Ferrandiz, Carlos, Daudén, Esteban, Sánchez-Carazo, Jose-Luis, Alsina, Mercé, Herrera-Ceballos, Enrique, Gómez-García, Francisco-José, Ferrán, Marta, López-Estebaranz, Jose-Luis, Hernanz, Jose-Manuel, Belinchón-Romero, Isabel, Vilar-Alejo, Jaime, Rivera, Raquel, Carrascosa, Jose-Manuel, and Carazo, Cristina

Published
2012
Full Text
View/download PDF

13. Disseminated skin nodules in a migrant patient

Author

Valenzuela-Oñate, Cristian, Magdaleno-Tapial, Jorge, Giacaman von der Weth, Macarena, Perez-Ferriols, Amparo, Sanchez Carazo, Jose Luis, Ricart-Olmos, Carmen, Herrera Cervera, Mario, Forteza Vila, Jeronimo, and Alegre de Miquel, Victor

Published
2019
Full Text
View/download PDF

15. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.

Author

HERNÁNDEZ-FERNÁNDEZ, Carlos Pelayo, CARRETERO, Gregorio, RIVERA, Raquel, FERRÁNDIZ, Carlos, DAUDÉN, Esteban, DE LA CUEVA, Pablo, BELINCHÓN, Isabel, GÓMEZ-GARCÍA, Francisco Javier, HERRERA-ACOSTA, Enrique, RUIZ-GENAO, Diana P., FERRÁN, MARTA, ALSINA, Mercé, BANIANDRÉS-RODRÍGUEZ, Ofelia, SÁNCHEZ-CARAZO, Jose Luis, BOTELLA-ESTRADA, Rafael, SAHUQUILLO-TORRALBA, Antonio, RODRIGUEZ, Lourdes, VILAR-ALEJO, Jaime, GARCÍA-DONOSO, Carmen, and CARRASCOSA, Jose M.

Subjects
PSORIASIS treatment, GENDER, PSORIASIS, TREATMENT effectiveness, DRUG prescribing
Abstract

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study.

Author

Sahuquillo-Torralba, Antonio, Carretero, Gregorio, Rivera, Raquel, Ferrándiz, Carlos, Daudén-Tello, Esteban, de la Cueva, Pablo, Gómez-García, Francisco José, Belinchón, Isabel, Herrera-Acosta, Enrique, Ruiz-Genao, Diana, Ferrán, Marta, Alsina, Mercé, Sánchez-Carazo, Jose Luís, Baniandrés, Ofelia, Fernández-Freire, Lourdes Rodríguez, Vilar, Jaime, García-Donoso, Carmen, Carrascosa, Jose Manuel, Llamas-Velasco, Mar, and Herrera-Ceballos, Enrique

Published
2020
Full Text
View/download PDF

19. Tissue inflammatory biomarkers in chronic plaque psoriasis: Exploring lesional versus non‐lesional skin relative expression and possible clinical correlations.

Author

Martínez‐Doménech, Alvaro, Hernández‐Bel, Pablo, García‐Legaz Martínez, Marta, Magdaleno‐Tapial, Jorge, Valenzuela‐Oñate, Cristian, Mata‐Roig, Manuel, Sánchez‐Carazo, Jose‐Luis, Alegre‐de Miquel, Víctor, and Pérez‐Ferriols, Amparo

Subjects
PSORIASIS, BIOMARKERS
Abstract

Psoriasis is a chronic inflammatory dermatosis affecting 2% of the world's population.[1] Though recognised for its expression on the skin, it is accompanied by chronic systemic inflammation. Relative expression levels of each biomarker are shown in Fig.. Statistical analysis showed significant differences between the biomarkers' relative expressions ( I P i < I i 0.001). None of the biomarkers correlated with BMI; however, relative expression of IL12p40 was higher among patients categorised as overweight or obese ( I P i = I i 0.039). [Extracted from the article]

Published
2020
Full Text
View/download PDF

21. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.

Author

García-Doval, Ignacio, Pérez-Zafrilla, Beatriz, Ferrandiz, Carlos, Carretero, Gregorio, Daudén, Esteban, de la Cueva, Pablo, Gómez-García, Francisco J, Herrera-Ceballos, Enrique, Belinchón-Romero, Isabel, Sánchez-Carazo, Jose Luis, López-Estebaranz, Jose-Luis, Alsina, Merce, Ferrán, Marta, Torrado, Rosa, Carrascosa, Jose-Manuel, Rivera, Raquel, and Vanaclocha, Francisco

Subjects
PSORIASIS treatment, THERAPEUTIC use of monoclonal antibodies, TUMOR necrosis factors, HEALTH outcome assessment, FOLLOW-up studies (Medicine)
Abstract

Background: Identifying patients likely to have very good or bad results from systemic psoriasis therapy could improve efficiency of therapy.Objective: To develop prognostic models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis.Methods: Multivariable logistic regression of a prospective multicenter cohort of psoriatic patients in clinical practice (6449 person-years of follow-up). We used as possible predictors demographic characteristics, comorbidities, characteristics of the psoriasis (type, PASI, arthritis), history of past therapy at entry in the cohort, and history of response to previous cycles while in the cohort. We defined good response to a treatment cycle as either cycle end due to disease remission or a cycle longer than 2 years that does not end later due to inefficacy in the follow-up period. Bad response to a treatment cycle was defined as a cycle that is finished due to inefficacy, based on the physician judgment, after more than 3 months of treatment.Results: Patients with fewer previous therapies, lower body mass index, older at start of therapy, and with previous history of good responses to therapy are more likely to have positive results of therapy. However, the predictive characteristics of models are poor.Conclusion: Predictive models of clinical response to systemic drugs in psoriasis with the studied variables do not seem to outperform drug selection by a dermatologist. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

22. Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study.

Author

Peñuelas Leal, Rodrigo, Bagan, Leticia, Grau Echevarría, Andrés, Peñuelas Ruiz, Jose Amancio, Zaragoza Ninet, Violeta, Sánchez Carazo, Jose Luis, Pérez Pastor, Gemma, Labrandero Hoyos, Carolina, Finello, Malena, Martínez Fernández, Sandra, Blaya Imbernon, Daniel, González García, Ángel, Pérez Zafrilla, Elena, Martí Cabrera, Miguel, and Bagan, Jose

Subjects
*ORAL mucosa diseases, *ORAL mucosa, *ORAL diseases, *PAIN management, *STOMATITIS
Abstract

Introduction Methods Results Conclusions Severe recurrent aphthous stomatitis (RAS) represents a therapeutic challenge because of its impact on the patient's quality of life. Additionally, no approved systemic therapies are available. Roflumilast, a phosphodiesterase‐4 inhibitor, has shown promise in other inflammatory dermatological conditions. This study aimed to assess the characteristics, effectiveness, and safety of roflumilast in treating RAS in routine clinical practice.This is a single cohort ambispective observational study conducted in five Spanish centers. Twenty‐two patients with RAS treated with roflumilast participated. Data collection included demographic, clinical, and outcome variables. Statistical analysis compared the outcomes of 12 weeks of roflumilast treatment with a similar prior period without treatment.During treatment with roflumilast, a significant reduction in flare‐ups (88%) and oral ulcers (94%) was observed compared to the untreated period. A reduction in pain (66%) and ulcer duration (63%) was observed. Adverse effects (AEs) occurred in 13 patients, predominantly headache and gastrointestinal disturbances. Most of these were self‐limiting or manageable with dose adjustment. Treatment was withdrawn in three cases, mainly because of AEs.This study suggests that roflumilast may effectively treat RAS by reducing the number of flare‐ups and ulcers, their duration, and the symptomatology produced by the ulcers. In addition, roflumilast has a good safety profile, is well tolerated at low doses, and does not require close monitoring. These characteristics and its favorable economic profile make roflumilast a promising therapeutic option in this pathology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Erythrodermic psoriasis and secukinumab: Our clinical experience.

Author

Mateu‐Puchades, Almudena, Santos‐Alarcón, Sergio, Martorell‐Calatayud, Antonio, Pujol‐Marco, Conrad, and Sánchez‐Carazo, Jose‐Luis

Subjects
PSORIASIS, MONOCLONAL antibodies, INTERLEUKINS, BODY temperature regulation, INFLAMMATION
Abstract

The article offers information on Erythrodermic Psoriasis, which is a particularly infrequent inflammatory form of psoriasis that affects most of the body surface area and characterized by a significant morbidity and even mortality, due to electrolyte abnormalities, nutritional status, impaired thermoregulation, and underlying infection. It is noted that secukinumab, a human IgG1 monoclonal antibody that binds to the protein interleukin, is found to be effective in treatment of patients.

Published
2018
Full Text
View/download PDF

28. Refractory Behçet disease succesfully treated with roflumilast.

Author

Peñuelas Leal R, Labrandero Hoyos C, Grau Echevarría A, Martínez-Doménech A, Casanova Esquembre A, Zaragoza Ninet V, Pérez Ferriols A, and Sánchez Carazo JL

Subjects
Humans, Aminopyridines therapeutic use, Benzamides therapeutic use, Cyclopropanes therapeutic use, Behcet Syndrome drug therapy
Abstract

Competing Interests: Conflicts of interest: the authors declare they have no conflicts of interest.

Published
2023
Full Text
View/download PDF

29. Interstitial granulomatous dermatitis in a patient with lupus erythematosus.

Author

García-Rabasco A, Esteve-Martínez A, Zaragoza-Ninet V, Sánchez-Carazo JL, and Alegre-de-Miquel V

Subjects
Administration, Oral, Adrenal Cortex Hormones administration & dosage, Adult, Dermatitis drug therapy, Dermatitis pathology, Female, Granuloma drug therapy, Granuloma pathology, Humans, Treatment Outcome, Arthritis complications, Dermatitis etiology, Granuloma etiology, Lupus Erythematosus, Systemic complications, Skin pathology
Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results